Personnel Information

写真a

KURATA Morito


Job title

Junior Associate Professor

Laboratory Phone number

+81-3-5803-5176

Mail Address

The inquiry by e-mail is 《here

Graduating School 【 display / non-display

  • Fukui Medical University, Faculty of Medicine, 2003.03, Graduated

Graduate School 【 display / non-display

  • Tokyo Medical and Dental University, Doctor's Course, 2007.03, Completed

Campus Career 【 display / non-display

  • 2007.04
    -
    2013.03
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Medical and Dental Sciences, Advanced Therapeutic Sciences, Comprehensive Pathology, Assistant Professor
  • 2013.04
    -
    2013.09
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Medical and Dental Sciences, Advanced Therapeutic Sciences, Comprehensive Pathology, Junior Associate Professor
  • 2016.09
    -
    Now
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Medical and Dental Sciences, Advanced Therapeutic Sciences, Comprehensive Pathology, Junior Associate Professor

External Career 【 display / non-display

  • 2013.10
    -
    2016.09
    University of Minnesota, Masonic Cancer Center, Research Scholar

Research Areas 【 display / non-display

  • Pathological medical chemistry

  • Experimental pathology

 

Published Papers & Misc 【 display / non-display

  • Yamamoto Akiko, Kurata Morito, Onishi Iichiroh, Sugita Keisuke, Matsumura Miwa, Ishibashi Sachiko, Ikeda Masumi, Yamamoto Kouhei, Kitagawa Masanobu. CRISPR screening identifies M1AP as a new MYC regulator with a promoter-reporter system PEERJ. 2020.05; 8 e9046. ( PubMed, DOI )

  • Morito Kurata, Kouhei Yamamoto, Branden S Moriarity, Masanobu Kitagawa, David A Largaespada. CRISPR/Cas9 library screening for drug target discovery. J. Hum. Genet.. 2018.02; 63 (2): 179-186. ( PubMed, DOI )

  • Yamamoto A, Kurata M, Yamamoto K, Nogawa D, Inoue M, Ishibashi S, Ikeda M, Miyasaka N, Kitagawa M. High amplification of PVT1 and MYC predict favorable prognosis in early ovarian carcinoma. Pathology, research and practice. 2020.08; 216 (11): 153175. ( PubMed, DOI )

  • Umemori M, Kurata M, Yamamoto A, Yamamoto K, Ishibashi S, Ikeda M, Tashiro K, Kimura T, Sato S, Takahashi H, Kitagawa M. The expression of MYC is strongly dependent on the circular PVT1 expression in pure Gleason pattern 4 of prostatic cancer. Medical molecular morphology. 2020.01; ( PubMed, DOI )

  • Morito Kurata, Natalie K Wolf, Walker S Lahr, Madison T Weg, Mitchell G Kluesner, Samantha Lee, Kai Hui, Masano Shiraiwa, Beau R Webber, Branden S Moriarity. Highly multiplexed genome engineering using CRISPR/Cas9 gRNA arrays. PLoS ONE. 2018.09; 13 (9): e0198714. ( PubMed, DOI )

display all >>

Conference Activities & Talks 【 display / non-display

  • 倉田 盛人, 山本 浩平, 北川 昌伸. PI3K変異型乳癌における新規協調癌遺伝子とシグナル探索(Discovery of cancer genes and pathways operative in PI3K activated mammary cancer). 日本癌学会総会記事 2019.09.01

  • 野川 大地, グリニサ・アヒマティ , 山本 阿紀子, 大西 威一郎, 倉田 盛人, 宮坂 尚幸, 山本 浩平, 北川 昌伸. 卵巣癌におけるMCM2タンパクの細胞内局在に着目した臨床病理学的検討(Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma). 日本癌学会総会記事 2019.09.01

  • 山本 浩平, 阿部 晋也, 倉田 盛人, 本田 彩華, 山本 正英, 北川 昌伸. ラノラジンは難治性悪性リンパ腫に対する有望な抗腫瘍薬としての可能性を有する(Ranolazine is a potential anti-tumor reagent against refractory cases in malignant lymphoma). 日本癌学会総会記事 2019.09.01

  • 野川 大地, グリニサ・アヒマティ , 山本 阿紀子, 立澤 杏奈, 峰尾 竜徳, 大西 威一郎, 倉田 盛人, 宮坂 尚幸, 山本 浩平, 北川 昌伸. 卵巣癌におけるMCM2タンパクの細胞内局在に着目した臨床病理学的検討(Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma). 日本病理学会会誌 2019.04.01

  • 山本 浩平, 阿部 晋也, 本田 彩華, 山本 正英, 三浦 修, 倉田 盛人, 北川 昌伸. ラノラジンは難治性悪性リンパ腫に対する有望な抗腫瘍薬としての可能性を有する(Ranolazine is a potential anti-tumor reagent against refractory cases in malignant lymphoma). 日本病理学会会誌 2019.04.01

display all >>